Bank of America Corp DE Increases Position in OptimizeRx Co. (NASDAQ:OPRX)

Bank of America Corp DE boosted its holdings in shares of OptimizeRx Co. (NASDAQ:OPRX - Free Report) by 54.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 73,934 shares of the company's stock after buying an additional 26,093 shares during the quarter. Bank of America Corp DE owned approximately 0.40% of OptimizeRx worth $359,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of OPRX. SBI Securities Co. Ltd. acquired a new stake in OptimizeRx in the fourth quarter valued at approximately $25,000. SG Americas Securities LLC acquired a new stake in OptimizeRx in the fourth quarter valued at approximately $51,000. Wells Fargo & Company MN boosted its stake in OptimizeRx by 33.3% in the fourth quarter. Wells Fargo & Company MN now owns 11,208 shares of the company's stock valued at $54,000 after acquiring an additional 2,797 shares in the last quarter. BNP Paribas Financial Markets boosted its stake in OptimizeRx by 504.6% in the fourth quarter. BNP Paribas Financial Markets now owns 22,308 shares of the company's stock valued at $108,000 after acquiring an additional 18,618 shares in the last quarter. Finally, Barclays PLC boosted its stake in OptimizeRx by 13.5% in the fourth quarter. Barclays PLC now owns 30,574 shares of the company's stock valued at $148,000 after acquiring an additional 3,640 shares in the last quarter. 76.47% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts have weighed in on OPRX shares. B. Riley restated a "buy" rating on shares of OptimizeRx in a research note on Tuesday, May 13th. Citigroup restated an "outperform" rating on shares of OptimizeRx in a research note on Tuesday, May 13th. JMP Securities raised their target price on shares of OptimizeRx from $11.00 to $14.00 and gave the company a "market outperform" rating in a research note on Tuesday, May 13th. Stifel Nicolaus raised their target price on shares of OptimizeRx from $12.50 to $16.00 and gave the company a "buy" rating in a research note on Monday, June 9th. Finally, Wall Street Zen upgraded shares of OptimizeRx from a "hold" rating to a "buy" rating in a research note on Thursday, May 22nd. Three investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. According to data from MarketBeat.com, OptimizeRx currently has a consensus rating of "Moderate Buy" and an average target price of $10.81.

OptimizeRx Stock Performance

Shares of NASDAQ:OPRX traded down $0.50 on Monday, hitting $13.77. 263,320 shares of the company were exchanged, compared to its average volume of 294,906. OptimizeRx Co. has a 1-year low of $3.78 and a 1-year high of $15.71. The stock's 50 day moving average price is $10.82 and its 200 day moving average price is $7.67. The company has a current ratio of 3.23, a quick ratio of 3.23 and a debt-to-equity ratio of 0.29. The firm has a market capitalization of $254.68 million, a P/E ratio of -10.35 and a beta of 1.34.

OptimizeRx (NASDAQ:OPRX - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The company reported $0.08 EPS for the quarter, topping the consensus estimate of ($0.11) by $0.19. OptimizeRx had a negative net margin of 27.41% and a negative return on equity of 4.92%. The business had revenue of $21.93 million during the quarter, compared to the consensus estimate of $18.69 million. Sell-side analysts predict that OptimizeRx Co. will post -0.33 EPS for the current year.

OptimizeRx Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.